linjc16/ctgov huggingface dataset:
Clinical Study of Impact of Different Pacing Site in Patients

Study Overview
=================
Brief Summary
-----------------
At present, cardiac pacing has been widely used in the treatment of bradyarrhythmias and heart failure, which can effectively improve the survival rate of patients. With the rapid development of technology, different sites can be chosen to pace, such as right atrial appendage, the atrial septum and the right atrial wall in the atrium, His bundle, left bundle branch area, right ventricular apex, outflow tract, and left ventricular pacing via coronary vein in the ventricle. There are few studies comparing the long-term efficacy and safety of different pacing sites in daily practice. This study aims to observe the efficacy and safety of cardiac pacing at different sites in short and long term, and to compare the advantages and disadvantages of pacing at different sites.

Official Title
-----------------
Clinical Study of Impact of Different Pacing Site in Patients

Conditions
-----------------
Bradyarrhythmias, Heart Failure, Pacemaker

Intervention / Treatment
-----------------
* Device: Pacemaker implantation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who received pacemaker implantation in the Second Hospital of Zhejiang Medical University by Pan Xiaohong and other surgeons. Patients who have the ability to understand the test and can cooperate with investigators. Exclusion Criteria: Patients who unable to understand or unwilling to fill in informed consent forms or follow visitors.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Pacemaker implantation|Different pacing sites will be chosen according to the patients condition.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Composite of Cardiovascular death, myocardial infarction, and stroke events | Composite of Cardiovascular death, myocardial infarction, and stroke events in 60 months | 60 months |
Digoxin Drug-Drug Interaction With Lurasidone HCl

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to evaluate the pharmacokinetic profile of digoxin when administered alone and when administered with repeated dose of lurasidone 120mg.

Official Title
-----------------
A Phase 1, Open-Label, Drug-Drug Interaction Study to Determine the Effect of Repeated Dose Lurasidone 120 mg Administration on the Pharmacokinetics of Orally Administered Digoxin 0.25 mg in Patients With Schizophrenia or Schizoaffective Disorder.

Conditions
-----------------
Schizophrenia

Intervention / Treatment
-----------------
* Drug: Lurasidone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and female 18 to 65 years of age BMI >= 19.5 and <= 37 kg/m2 No clinically relevant abnormal laboratory values Exclusion Criteria: History or presence of renal or hepatic insufficiency Participated in a clinical trial in the past 30 days Use of con meds that prolong the QT/QTc taken within 28 days prior to study drug administration

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Lurasidone|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Lurasidone, Schizophrenia, Latuda
Trial of Adjunctive Vitamin D in Tuberculosis Treatment

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether vitamin D enhances response to standard antibiotic treatment for pulmonary tuberculosis.

Official Title
-----------------
Trial of Adjunctive Vitamin D in Tuberculosis Treatment

Conditions
-----------------
Tuberculosis, Pulmonary

Intervention / Treatment
-----------------
* Drug: Cholecalciferol
* Drug: Migliol Placebo Oil


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Suspected smear positive pulmonary tuberculosis. Age 18 years or older. Written informed consent to participate. Exclusion Criteria: Known intolerance of vitamin D or first-line anti-tuberculous therapy. Taking antituberculous therapy for more than six days in the six months preceding enrolment. Taking the following medication in the month preceding enrolment: oral corticosteroid therapy, immunosuppressant therapy or cytotoxic therapy. Taking the following medication at enrolment: benzothiadiazine derivatives, cardiac glycosides or antituberculous therapy other than rifampicin, isoniazid, pyrazinamide and ethambutol. Diagnosis of any of the following: sarcoidosis, hyperparathyroidism, nephrolithiasis, pulmonary silicosis, HIV infection, liver failure, renal failure or malignancy Infection with rifampicin-resistant organism (as demonstrated by rapid molecular testing) Biochemical disturbance at enrolment: serum corrected calcium >2.66 mmol/l, serum AST >120 IU/l, total serum bilirubin > 40 micromol/l or serum creatinine > 250 micromol/l Breastfeeding or pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Cholecalciferol|nan|
|Drug: Migliol Placebo Oil|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to sputum culture conversion |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of bacillary kill |  |  | 
| 2-month culture conversion rate |  |  | 
| Time to sputum smear conversion |  |  | 
| Weight change |  |  | 
| Radiographic response |  |  |
Triton Reference Database

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to collect OCT measurement data on normal healthy eyes.

Detailed Description
-----------------
The objective of this study is to collect OCT measurement data on normal healthy eyes in order to determine the reference limits for Topcon DRI OCT Triton based on the percentile points for 1%, 5%, 95%, and 99%.

Official Title
-----------------
Topcon DRI OCT Triton Reference Database Study

Conditions
-----------------
Healthy Eyes

Intervention / Treatment
-----------------
* Device: Topcon DRI OCT Triton (plus)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Subjects 18 years of age or older on the date of informed consent Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent Subjects presenting at the site with normal eyes bilaterally (cataracts are acceptable) IOP ≤ 21 mmHg bilaterally BCVA 20/40 or better bilaterally Exclusion Criteria Subjects unable to tolerate ophthalmic imaging Subjects with ocular media not sufficiently clear to obtain acceptable OCT images HFA visual field (24-2 Sita Standard, white on white) result unreliable (based on manufacturer's recommendation), defined as fixation losses > 20% or false positives > 33%, or false negatives > 33% Visual field defects consistent with glaucomatous optic nerve damage based on at least one of the following two findings: On pattern deviation (PD), there exists a cluster of 3 or more points in an expected location of the visual field depressed below the 5% level, at least 1 of which is depressed below the 1% level; Glaucoma hemi-field test outside normal limits. Narrow angle History of leukemia, dementia or multiple sclerosis Concomitant use of hydroxychloroquine and chloroquine

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Subjects Presenting With Normal Eyes<br>Subjects with no known ocular diseases will be scanned on the Topcon DRI OCT Triton (plus) device | Device: Topcon DRI OCT Triton (plus)<br>* OCT Machine used for diagnostic purposes<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retinal Thickness | The thickness of the macula layer | 1 Minute | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
no known ocular pathology
PRP Intrauterine Infusion in Thawed Embryo Cycles

Study Overview
=================
Brief Summary
-----------------
All patients prepared to thawed embryo transfer were classified into 2 groups one group will receive platelet rich plasma (PRP) infusion intrauterine and the other group will not receive platelet rich plasma (PRP) infusion

Detailed Description
-----------------
Patients candidates for Thawed embryo transfer with Repeated implantation failure were recruited from 3 centers and classified into 2 groups: Group I: Will receive platelet rich plasma (PRP) intrauterine infusion at day 11 Group II: Not receiving platelet rich plasma (PRP)

Official Title
-----------------
Intrauterine Infusion of Platelet-rich Plasma Infusion Before Thawed Embryo Transfer in Repeated Implantation Failure: A Randomized Controlled Study

Conditions
-----------------
Evaluations

Intervention / Treatment
-----------------
* Biological: Platelet rich plasma intrauterine infusion
* Biological: Normal saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients age 20-35 years Patients with previous implantation failure Patients with thin endometrium<7 mm Exclusion Criteria: Patients older than 40 years Patients with fresh embryo transfer Patients with abnormal uterine cavity septate, or bicornuate uterus Patients with abnormal male factor or tubal factor Patients with abnormal embryos grade B or C. Patients with immunological disorders as thyroidits or systemic lupus or rheumatoid arthritis

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: 2 groups parallel
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: PRP group<br>These patients will receive platelet rich plasma intrauterine infusion at day 11 | Biological: Platelet rich plasma intrauterine infusion<br>* platelet rich plasma will be prepared, activated then infused by Intrauterine insemination catheter intrauterine at day 11<br>|
| Placebo Comparator: Control group<br>These patients will receive intrauterine normal saline infusion at day 11 | Biological: Normal saline<br>* Intrauterine infusion of normal saline at day 11<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Endometrial thickness | The increase in endometrial thickness at day of ET | 8 days | 
| Pregnancy rate | Number of cases who got pregnant | 15 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Platelet rich plasma, Intrauterine infusion, Thawed embryos, IVF/ICSI cycles
Consequences and Correlates of Weight Fluctuations

Study Overview
=================
Brief Summary
-----------------
To quantify the association between multiple intentional weight losses (i.e., weight fluctuations) and the development of hypertension and diabetes mellitus among 50,790 female nurses participating in the ongoing Nurses' Health Study II. In addition to assessing the consequences of weight fluctuations, their correlates and course were identified.

Detailed Description
-----------------
BACKGROUND: In the United States, approximately one third of adult women are trying to lose weight. Most weight losses are not sustained and in fact may be followed by gains of at least as much weight as was intentionally lost. It is unclear whether there are adverse outcomes associated with multiple intentional weight losses. DESIGN NARRATIVE: The prospective study addressed the impact of weight fluctuation on development of hypertension (HPT) and diabetes (DM) by following women who significantly fluctuated in weight compared to those who generally maintained a stable weight. The subject source was all participants between 1989 and 1993 in the Nurses Health Study II (NHS) who did not experience a full term pregnancy between 1989 and 1993 and who were free of HPT, DM and cancer in 1993. A random sample of each of two weight fluctuation classifications, >20 lbs. (3 or more times) and 10-19 lbs. (3 or more times) was identified. A control group of non-fluctuators was matched by age and body mass index strata. Baseline data consisted of information obtained from the 1993 NHS II follow-up along with supplemental questionnaires sent to study participants to elicit specific information on past and present weight gain/loss and intentionality of weight fluctuation. Prospective data came from follow-up questionnaires in 1995, 1997, and 1999. Hypertension and DM ascertainment were obtained from self-report in the questionnaire. This ascertainment method appeared quite adequate based on validity studies carried out on subsamples of this cohort. The study completion date listed in this record was obtained from the End Date entered in the Protocol Registration and Results System (PRS) record.

Conditions
-----------------
Cardiovascular Diseases, Diabetes Mellitus, Heart Diseases, Hypertension

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Descriptive Study of the Incidence and Outcome of PAS in Two Large Referral Hospitals in Egypt

Study Overview
=================
Brief Summary
-----------------
placenta accreta spectrum incidence and outcome

Detailed Description
-----------------
placenta accreta spectrum ( PAS ) one of the most serious condition in obstetrics nowadays so the investigators measure the incidence by this study

Official Title
-----------------
Descriptive Study of the Incidence and Outcome of PAS in Two Large Referral Hospitals in Egypt , Kasr Alainy Hospital , Cairo University , and Banisuef Specialized Hospital in Last 6 Years

Conditions
-----------------
Placenta Accreta

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: gestational age above 28 weeks Exclusion Criteria: age less than 18

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of diagnosed pregnant women with placenta accreta spectrum | pregnant women with gestitional age above 18 week , with confirmed diagnosis with PAS with U/S | in last 6 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of hystrectomy | hystrectomy VS conservative management | in last 6 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PAS
Satiety Effects of Protein and Fiber Added to Pasta

Study Overview
=================
Brief Summary
-----------------
The combination of fiber and protein added to pasta will enhance satiety.

Detailed Description
-----------------
Subjects will consume 3 different pasta lunches and satiety will be measured by visual analogue scales. They will consume an ad lib snack after 3 hours and food intake will be measured.

Official Title
-----------------
Satiety Effects of Protein and Fiber Added to Pasta

Conditions
-----------------
Food Selection

Intervention / Treatment
-----------------
* Other: Pasta with protein
* Other: Pasta with Fiber
* Other: Pasta


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy nonsmoking body mass index from 19 - 29 Exclusion Criteria: Antibiotic use any disease weight loss food allergies high fiber intake restrained eater

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: pasta<br>1. Plain pasta | Other: Pasta<br>* Pasta<br>|
| Other: pasta with protein<br>Pasta with protein | Other: Pasta with protein<br>* Pasta with Protein<br>|
| Other: pasta with fiber<br>Pasta with Fiber | Other: Pasta with Fiber<br>* Pasta with Fiber<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| satiety |  | 180 minutes |
Role of CXCR2 Ligands/CXCR2 Biological Axis in Pancreatic Cancer

Study Overview
=================
Brief Summary
-----------------
The investigators hypothesize that the CXCR2 ligands/CXCR2 biological axis plays an important role in promoting angiogenesis in PC; and that the genetic changes and the microenvironment of the tumor regulate the expression of CXCR2 ligands/CXCR2 in PC in order to potentiate their angiogenic phenotype. A corollary of this hypothesis is that the cell surface receptors (CXCR2) and the intracellular signaling pathways that mediate the angiogenic responses induced by ELR+ CXC-chemokines are potential targets for novel therapeutic interventions in PC.

Official Title
-----------------
Role of CXCR2 Ligands/CXCR2 Biological Axis in Pancreatic Cancer

Conditions
-----------------
Chronic Pancreatitis, Pancreatic Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Normal subjects - No documented clinical history of pancreatic diseases supported by at least 1 negative imaging test. (EUS, Ct scan or MRI) Chronic pancreatitis - Documented diagnosis of moderate to advanced chronic supported bpancreatitisy at least 1 positive imaging test. (EUS, Ct scan or MRI) Pancreatic Cancer - Documented tissue diagnosis (or clinical suspicion) of Pancreatic Cancer. Exclusion Criteria: Exclusion criteria will include age younger than 18 yrs, pregnancy, previous pancreatic or gastric resection, and inability to tolerate routine endoscopy with conscious sedation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1. Normal pancreas patients<br>Patients with no documented clinical history of pancreatic diseases supported by at least 1 negative imaging test (EUS, CT scan or MRI). | |
| 2. Chronic pancreatitis patients<br>Patients with documented diagnosis of moderate to advanced chronic pancreatitis supported by at least 1 positive imaging test (EUS,CT scan or MRI). | |
| 3. Pancreatic cancer patients<br>Patients with documented tissue diagnosis (or clinical suspicion) of Pancreatic Cancer. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All cause mortality |  | One year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| For pancreatic patients from whom tissue samples will be available, we will examine the association between presence/absence of each marker in the tissue versus the marker level in blood and in pancreatic juice. |  | One year |